Activation of p38 MAPK-regulated Bcl-xL signaling increases survival against zoledronic acid-induced apoptosis in osteoclast precursors

Bone

Volumn 67, Issue , 2014, Pages 166-174

  Tai, Ta Wei ^a,b,c   Su, Fong Chin ^a   Chen, Ching Yu ^b   Jou, I Ming ^b   Lin, Chiou Feng ^d,e  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c Tainan Hospital   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Bcl xL; Osteoclast precursor; Osteoporosis; P38 MAPK; Zoledronic acid; Catenin

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3BETA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN BCL XL; ZOLEDRONIC ACID; BCL2L1 PROTEIN, MOUSE; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; PROTEIN BCL X;

ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE DENSITY; BONE STRENGTH; CELL CYCLE; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DNA FRAGMENTATION; ENZYME ACTIVATION; FEMALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; POLYMERIZATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION; STEM CELL; WESTERN BLOTTING; ANIMAL; CELL LINE; CYTOLOGY; DRUG EFFECTS; GENETICS; METABOLISM;

ANIMALS; APOPTOSIS; BCL-X PROTEIN; BLOTTING, WESTERN; CELL CYCLE; CELL LINE; CELL PROLIFERATION; DIPHOSPHONATES; IMIDAZOLES; MICE; OSTEOCLASTS; P38 MITOGEN-ACTIVATED PROTEIN KINASES;

EID: 84904888467     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.07.003     Document Type: Article

References (60)

1. Kanis J.A. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002, 359:1929-1936.
2. Benford H.L., McGowan N.W., Helfrich M.H., Nuttall M.E., Rogers M.J. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 2001, 28:465-473.
3. Rabenda V., Hiligsmann M., Reginster J.Y. Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opin Pharmacother 2009, 10:2303-2315.
4. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809-1822.
5. Coxon F.P., Helfrich M.H., Van't Hof R., Sebti S., Ralston S.H., Hamilton A., et al. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 2000, 15:1467-1476.
6. Recker R.R., Delmas P.D., Halse J., Reid I.R., Boonen S., Garcia-Hernandez P.A., et al. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 2008, 23:6-16.
7. Lyles K.W., Colon-Emeric C.S., Magaziner J.S., Adachi J.D., Pieper C.F., Mautalen C., et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007, 357:1799-1809.
8. Sebba A.I. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment. Clin Ther 2008, 30:443-452.
9. Hochberg M.C., Ross P.D., Black D., Cummings S.R., Genant H.K., Nevitt M.C., et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 1999, 42:1246-1254.
10. Watts N.B., Cooper C., Lindsay R., Eastell R., Manhart M.D., Barton I.P., et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom 2004, 7:255-261.
11. Lewiecki E.M. Nonresponders to osteoporosis therapy. J Clin Densitom 2003, 6:307-314.
12. Carey J.J. What is a 'failure' of bisphosphonate therapy for osteoporosis?. Cleve Clin J Med 2005, 72:1033-1039.
13. Bonnick S., Saag K.G., Kiel D.P., McClung M., Hochberg M., Burnett S.M., et al. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab 2006, 91:2631-2637.
14. Reginster J.Y., Adami S., Lakatos P., Greenwald M., Stepan J.J., Silverman S.L., et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2year results from the MOBILE study. Ann Rheum Dis 2006, 65:654-661.
15. Miller P.D., McClung M.R., Macovei L., Stakkestad J.A., Luckey M., Bonvoisin B., et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005, 20:1315-1322.
16. Sebba A.I., Bonnick S.L., Kagan R., Thompson D.E., Skalky C.S., Chen E., et al. Fosamax Actonel Comparison Trial i. Response to therapy with once-weekly alendronate 70mg compared to once-weekly risedronate 35mg in the treatment of postmenopausal osteoporosis. Curr Med Res Opin 2004, 20:2031-2041.
17. Nieto E., Cerrada L., Salinas J.R. One year zoledronic acid therapy in postmenopausal osteoporosis. Internet J. Intern. Med. 2007, 7.
18. Jacques R.M., Boonen S., Cosman F., Reid I.R., Bauer D.C., Black D.M., et al. Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5mg: the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012, 27:1627-1634.
19. Black D.M., Reid I.R., Boonen S., Bucci-Rechtweg C., Cauley J.A., Cosman F., et al. The effect of 3 versus 6years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012, 27:243-254.
20. Kars M.D., Iseri O.D., Ural A.U., Gunduz U. In vitro evaluation of zoledronic acid resistance developed in MCF-7 cells. Anticancer Res 2007, 27:4031-4037.
21. Milone M.R., Pucci B., Bruzzese F., Carbone C., Piro G., Costantini S., et al. Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells. Cell Death Dis 2013, 4:e641.
22. Morii T., Ohtsuka K., Ohnishi H., Mochizuki K., Satomi K. Inhibition of heat-shock protein 27 expression eliminates drug resistance of osteosarcoma to zoledronic acid. Anticancer Res 2010, 30:3565-3571.
23. Ory B., Moriceau G., Trichet V., Blanchard F., Berreur M., Redini F., et al. Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells. J Cell Mol Med 2008, 12:928-941.
24. Zhang Q., Badell I.R., Schwarz E.M., Boulukos K.E., Yao Z., Boyce B.F., et al. Tumor necrosis factor prevents alendronate-induced osteoclast apoptosis in vivo by stimulating Bcl-xL expression through Ets-2. Arthritis Rheum 2005, 52:2708-2718.
25. Hsing C.H., Chen Y.H., Chen C.L., Huang W.C., Lin M.C., Tseng P.C., et al. Anesthetic propofol causes glycogen synthase kinase-3beta-regulated lysosomal/mitochondrial apoptosis in macrophages. Anesthesiology 2012, 116:868-881.
26. Tseng P.C., Huang W.C., Chen C.L., Sheu B.S., Shan Y.S., Tsai C.C., et al. Regulation of SHP2 by PTEN/AKT/GSK-3beta signaling facilitates IFN-gamma resistance in hyperproliferating gastric cancer. Immunobiology 2012, 217:926-934.
27. Shortt J., Johnstone R.W. Oncogenes in cell survival and cell death. Cold Spring Harb Perspect Biol 2012, 4.
28. Cory S., Huang D.C., Adams J.M. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003, 22:8590-8607.
29. Kubo T., Shimose S., Matsuo T., Sakai A., Ochi M. Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells. Cancer Chemother Pharmacol 2008, 62:111-116.
30. Merrell M.A., Wakchoure S., Lehenkari P.P., Harris K.W., Selander K.S. Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells. Eur J Pharmacol 2007, 570:27-37.
31. Ding Y., Shen S., Lino A.C., Curotto de Lafaille M.A., Lafaille J.J. Beta-catenin stabilization extends regulatory T cell survival and induces anergy in nonregulatory T cells. Nat Med 2008, 14:162-169.
32. Xie H., Huang Z., Sadim M.S., Sun Z. Stabilized beta-catenin extends thymocyte survival by up-regulating Bcl-xL. J Immunol 2005, 175:7981-7988.
33. Zhang N., Wei P., Gong A., Chiu W.T., Lee H.T., Colman H., et al. FoxM1 promotes beta-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell 2011, 20:427-442.
34. Graham J.A., Fray M., de Haseth S., Lee K.M., Lian M.M., Chase C.M., et al. Suppressive regulatory T cell activity is potentiated by glycogen synthase kinase 3{beta} inhibition. J Biol Chem 2010, 285:32852-32859.
35. Bikkavilli R.K., Feigin M.E., Malbon C.C. p38 mitogen-activated protein kinase regulates canonical Wnt-beta-catenin signaling by inactivation of GSK3beta. J Cell Sci 2008, 121:3598-3607.
36. Thornton T.M., Pedraza-Alva G., Deng B., Wood C.D., Aronshtam A., Clements J.L., et al. Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivation. Science 2008, 320:667-670.
37. Li X., Udagawa N., Itoh K., Suda K., Murase Y., Nishihara T., et al. p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. Endocrinology 2002, 143:3105-3113.
38. Abe K., Yoshimura Y., Deyama Y., Kikuiri T., Hasegawa T., Tei K., et al. Effects of bisphosphonates on osteoclastogenesis in RAW264.7 cells. Int J Mol Med 2012, 29:1007-1015.
39. Busca A., Saxena M., Kumar A. Critical role for antiapoptotic Bcl-xL and Mcl-1 in human macrophage survival and cellular IAP1/2 (cIAP1/2) in resistance to HIV-Vpr-induced apoptosis. J Biol Chem 2012, 287:15118-15133.
40. Kremer K.N., Peterson K.L., Schneider P.A., Meng X.W., Dai H., Hess A.D., et al. CXCR4 chemokine receptor signaling induces apoptosis in acute myeloid leukemia cells via regulation of the Bcl-2 family members Bcl-XL, Noxa, and Bak. J Biol Chem 2013, 288:22899-22914.
41. Shimizu S., Takehara T., Hikita H., Kodama T., Miyagi T., Hosui A., et al. The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. J Hepatol 2010, 52:698-704.
42. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435:677-681.
43. + leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci U S A 2006, 103:14907-14912.
44. Faust D., Schmitt C., Oesch F., Oesch-Bartlomowicz B., Schreck I., Weiss C., et al. Differential p38-dependent signalling in response to cellular stress and mitogenic stimulation in fibroblasts. Cell Commun. Signal. 2012, 10:6.
45. Yamashita T., Kobayashi Y., Mizoguchi T., Yamaki M., Miura T., Tanaka S., et al. MKK6-p38 MAPK signaling pathway enhances survival but not bone-resorbing activity of osteoclasts. Biochem Biophys Res Commun 2008, 365:252-257.
46. Medicherla S., Ma J.Y., Mangadu R., Jiang Y., Zhao J.J., Almirez R., et al. A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis. J Pharmacol Exp Ther 2006, 318:132-141.
47. Zwerina J., Hayer S., Redlich K., Bobacz K., Kollias G., Smolen J.S., et al. Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction. Arthritis Rheum 2006, 54:463-472.
48. Mbalaviele G., Anderson G., Jones A., De Ciechi P., Settle S., Mnich S., et al. Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction. J Pharmacol Exp Ther 2006, 317:1044-1053.
49. Wang X., Liu J.Z., Hu J.X., Wu H., Li Y.L., Chen H.L., et al. ROS-activated p38 MAPK/ERK-Akt cascade plays a central role in palmitic acid-stimulated hepatocyte proliferation. Free Radic Biol Med 2011, 51:539-551.
50. Wang W., Chen J.X., Liao R., Deng Q., Zhou J.J., Huang S., et al. Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence. Mol Cell Biol 2002, 22:3389-3403.
51. Trosset J.Y., Dalvit C., Knapp S., Fasolini M., Veronesi M., Mantegani S., et al. Inhibition of protein-protein interactions: the discovery of druglike beta-catenin inhibitors by combining virtual and biophysical screening. Proteins 2006, 64:60-67.
52. Sutherland K.A., Rogers H.L., Tosh D., Rogers M.J. RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro. Arthritis Res Ther 2009, 11:R58.
53. Ritchlin C.T., Schwarz E.M., O'Keefe R.J., Looney R.J. RANK, RANKL and OPG in inflammatory arthritis and periprosthetic osteolysis. J Musculoskelet Neuronal Interact 2004, 4:276-284.
54. Breuil V., Euller-Ziegler L. Bisphosphonate therapy in rheumatoid arthritis. Joint Bone Spine 2006, 73:349-354.
55. Lelovas P.P., Xanthos T.T., Thoma S.E., Lyritis G.P., Dontas I.A. The laboratory rat as an animal model for osteoporosis research. Comp Med 2008, 58:424-430.
56. Bellido T., Plotkin L.I. Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability. Bone 2011, 49:50-55.
57. Plotkin L.I., Lezcano V., Thostenson J., Weinstein R.S., Manolagas S.C., Bellido T. Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res 2008, 23:1712-1721.
58. Plotkin L.I., Weinstein R.S., Parfitt A.M., Roberson P.K., Manolagas S.C., Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999, 104:1363-1374.
59. Basso F.G., Silveira Turrioni A.P., Hebling J., de Souza Costa C.A. Zoledronic acid inhibits human osteoblast activities. Gerontology 2013, 59:534-541.
60. Greiner S., Kadow-Romacker A., Lubberstedt M., Schmidmaier G., Wildemann B. The effect of zoledronic acid incorporated in a poly(D, L-lactide) implant coating on osteoblasts in vitro. J Biomed Mater Res A 2007, 80:769-775.